← Leaderboards
Hsiaoju Sharon Lee
Trevarx Biomedical, Inc.
$1,531,520
Attributed
$2,738,040
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,738,040 · 3
By mechanism
R42$2,022,982 · 1
R41$390,058 · 1
R21$325,000 · 1
Top collaborators
- Michel Mikhail2 shared
- Sally Wagner Schwarz1 shared
Most similar at Trevarx Biomedical, Inc.
Same institution · by research overlap
- Michel Mikhail$1,011,491
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsTumorAnalogRadiopharmaceuticalsMalignant NeoplasmsClinical TranslationProductionUptakeIn VivoMulti-Institutional Clinical TrialGenesMulticenter TrialsBreastGene MutationOvarianLeadCompanion DiagnosticsMalignant Breast NeoplasmClinical TrialsImageDesignLabelBindingEnsure
Grant awards (4)
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution$979,093
R42 · FY2024 · CA
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution$1,043,889
R42 · FY2023 · CA
Novel chemistry to improve the biostability of organo-astatine bonds in alpha-emitting radiopharmaceutical therapeutics$325,000
R21 · FY2022 · EB · contact PI
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution$390,058
R41 · FY2021 · CA